How the diversified business model of Catalent, Inc (XNYS:CTLT) provides a safe investment opportunity?

How the diversified business model of Catalent, Inc (XNYS:CTLT) provides a safe investment opportunity?

ByMarketFacts

Catalent, Inc. (NYSE: CTLT) is a leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. Operating as a Contract Development and Manufacturing organization (CDMO), the company serves a wide range of customers in the pharmaceutical, biotech, and consumer health industries.
It operates under four main segments: biologics, softgel and oral technologies, oral and specialty delivery, and clinical supply services. The company is known for its expertise in developing and manufacturing complex and difficult-to-formulate products, and for its ability to rapidly scale up production to meet the needs of its customers.

Why this satellite communications stock should be on your radar: Globalstar, Inc (XNYS:GSAT)

Why this satellite communications stock should be on your radar: Globalstar, Inc (XNYS:GSAT)

ByMarketFacts

Globalstar, Inc. (XNYS: GSAT) is a provider of mobile satellite voice and data services. The company operates a low Earth orbit (LEO) satellite constellation, which it uses to provide communications services to customers in remote and hard-to-reach areas. Globalstar’s services include satellite voice and data communications, asset tracking, and remote sensing. The company’s products include satellite phones, modems, and tracking devices, as well as a range of airtime and service plans. Globalstar was founded in 1991 and is headquartered in Covington, Louisiana.

Is it the right time to invest in this dividend growth stock :Medical Properties Trust, Inc. (XNYS:MPW)?

Is it the right time to invest in this dividend growth stock :Medical Properties Trust, Inc. (XNYS:MPW)?

ByMarketFacts

Medical Properties Trust Inc. (XNYS: MPW) is a REIT focused on healthcare facilities. One aspect of the company’s operations is the ownership and leasing of healthcare facilities. The United States generates the great majority of medical’s income, followed by Germany and the United Kingdom. Investment in mergers and acquisitions is a component of the company’s operational growth plan.

It offers to fund for a range of institutions requiring capital for acquisitions, sale-leasebacks, new developments, and expansion projects. Medical Properties Trust is committed to delivering strong financial results to its shareholders through a combination of steady cash flow, asset appreciation, and dividend growth

Why should this fast-growing large-cap stock be a part of your portfolio:Marvell Technology, Inc. (NASDAQ:MRVL)?

Why should this fast-growing large-cap stock be a part of your portfolio:Marvell Technology, Inc. (NASDAQ:MRVL)?

ByMarketFacts

Marvell Technology, Inc. (XNAS: MRVL) is a semiconductor and associated technology developer and manufacturer based in Santa Clara, California, specializing in networking and storage applications. Founded in 1995, the corporation has over 6,000 workers as of 2021, over 10,000 patents globally, and $4.5 billion in yearly sales. Marvell provides processors, optical connectors, application-specific integrated circuits (ASICs), and merchant silicon for Ethernet applications to the data center, carrier, corporate, automotive, and consumer end markets. The company is an aggressive buyer, with five significant acquisitions since 2017 assisting it in pivoting away from older consumer apps and into the cloud and 5G sectors. 

Is this clean energy producer stock worth a buy right now: Gevo Inc. (NASDAQ:GEVO)?

Is this clean energy producer stock worth a buy right now: Gevo Inc. (NASDAQ:GEVO)?

ByMarketFacts

Gevo Inc. (XNAS: GEVO) is a renewable chemicals and biofuel company that develops and commercializes alternatives to petroleum-based goods based on isobutanol derived from renewable feedstocks. Its operational segments include the Gevo sector, the Renewable Natural Gas segment, the Net-Zero segment, and the Agri-Energy business. It is engaged in research and development efforts linked to the future production of isobutanol, including developing its biocatalysts, manufacturing and selling biojet fuel, and creating biocatalysts. Gevo Development/Agri-Energy is the most important revenue-generating business, consisting of the operation of the Luverne Facility and the manufacture of ethanol, isobutanol, and associated products. 

Is STEM a hallmark for clean energy solutions: Stem, Inc. (XNYS:STEM)?

Is STEM a hallmark for clean energy solutions: Stem, Inc. (XNYS:STEM)?

ByMarketFacts

Stem, Inc. (XNYS:STEM) provides clean energy solutions and services designed to maximize the economic, environmental, and resiliency value of energy assets and portfolios. It operates as a digitally connected and intelligent energy storage network provider in the United States and internationally. It offers energy storage systems sourced from original equipment manufacturers (OEMs).

The company also provides Athena, an artificial intelligence platform, which offers battery hardware and software-enabled services to operate the energy storage systems.

What makes Hannon Armstrong (XNYS:HASI) a textbook buy stock?

What makes Hannon Armstrong (XNYS:HASI) a textbook buy stock?

ByMarketFacts

Hannon Armstrong Sustainable Infrastructure Capital Inc (XNYS: HASI) finances the US energy markets using debt and equity. The company’s investments are divided into energy-efficiency initiatives and renewable-energy projects. Energy-efficiency initiatives lower the energy usage and expense of a building or facility by improving or installing building components such as heating, ventilation, and air conditioning systems, lighting, energy controls, roofs, windows, building shells, and heat and power systems. Renewable-energy projects use greener energy sources like solar and wind to create electricity. The organization also offers finance for other initiatives to improve energy efficiency and the environment. 

Is this the right energy stock to generate dividend income: Emera Inc. (XTSE:EMA)?

Is this the right energy stock to generate dividend income: Emera Inc. (XTSE:EMA)?

ByMarketFacts

Emera Inc. (XTSE: EMA) is a geographically diverse energy and services company with interests in electricity generation, transmission, and distribution, as well as gas transmission and utility energy services. The company operates in five reportable segments throughout North America and the Caribbean: Florida Electric Utility, Canadian Electric Utilities, Other Electric Utilities, Gas Utilities and Infrastructure, and Others. The Florida Electric Utility comprises Tampa Electric, an electric utility serving customers in West Central Florida that is vertically integrated and regulated. The Company’s subsidiaries are Grand Bahama Power Company and Barbados Light & Power Company. The Company also owns St. Lucia Electricity Services Limited and Emera Caribbean Renewables Limited.

The Future of Cannabis!

The Future of Cannabis!

ByMarketFacts

Cannabis sales in the U.S. are expected to exceed $33 million in 2022 and reach $52 billion by the end of 2026, according to industry analysis. With market uncertainty lingering, some investors around the world are getting discouraged due to recurring losses in almost all sectors. However, investors with a long-term perspective see this situation as a great investment opportunity.

Among other fast-growing industries, including healthcare, technology, finance and more, cannabis is one industry with great potential for growth.

Can this cancer- curing company provide relief to your portfolio: Y-mAbs Therapeutics Inc. (NASDAQ: YMAB)?

Can this cancer- curing company provide relief to your portfolio: Y-mAbs Therapeutics Inc. (NASDAQ: YMAB)?

ByMarketFacts

Y-mAbs Therapeutics Inc. (XNAS: YMAB), incorporated in 2015 and headquartered in New York is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel antibody-based therapeutic cancer products. In addition to conventional antibodies, the Company’s technologies include bispecific antibodies generated using the Y-BiClone platform and the SADA platform.

The Company’s broad and advanced product pipeline includes one FDA-approved product, DANYELZA, which targets tumors that express GD2, and one product candidate at the registration stage, OMBLASTYS, which targets tumors that express B7-H3.